Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
WESA1d
Penn expecting $467M windfall from COVID-19 vaccine royalty dispute
The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...
University of Sheffield2d
The University of Sheffield homepage
If you want to study at the University of the Year 2024 (Whatuni Student Choice Awards), ranked 5th in the UK for job prospects (Student Crowd Awards 2024), apply now to start in September 2025. At ...
BUCKSCO.Today on MSN3d
BioNTech Agrees to Pay $467M to Penn as Part of COVID-19 Vaccine Royalties Settlement
University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...
FiercePharma4d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
BioPharma Dive4d
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.